|
Aurobindo Pharma has
reported excellent results for the quarter ended
31st December 2003. |
|
The Total Income for
the third quarter stood at Rs.32639 lakhs
(Rs.30172 lakhs) and for the nine month period
stood at Rs. 99168 lakhs (Rs.86046 lakhs). |
|
The Profit before
Tax for the third quarter stood at Rs.4773 lakhs
(Rs.2940 lakhs), an increase of 62% and the
Profit after tax for the third quarter stood at
Rs. 3562 lakhs (Rs.2115 lakhs), an increase of
68% over the corresponding quarter in the
previous year. |
|
The profit before
tax and the profit after tax for the nine-month
period stood at Rs. 12328 lakhs (Rs.7873 lakhs)
and Rs.9080 lakhs (Rs.5677 lakhs) registering a
sharp increase of 57% and 60 % respectively over
the corresponding period in the previous year. |
|
Net profit as a
percentage to sales for Q3 stood at 10.9%(7%)
and for the nine month period stood at 9.2%
(6.6%) |
|
Ratios |
Q3 of |
9 Months of
|
Year ended |
| |
FY 03-04 |
FY 02-03 |
FY 03-04 |
FY 02-03 |
FY 02-03 |
|
PBDIT / Total
Income (%) |
19.80% |
14.32% |
17.30% |
14.27% |
16.95% |
|
PBT/Total Income
(%) |
14.62% |
9.74% |
12.43% |
9.15% |
11.54% |
|
PAT/Total Income
(%) |
10.91% |
7.01% |
9.16% |
6.60% |
8.49% |
|
|
The exports
constitute Rs.16454 lakhs representing 51% of
the 3rd Quarter sales. |
|
The company’s
restructuring programme to emerge as a leading
company in emerging markets and penetrate into
US/EU markets is progressing well. |
|
The operating
efficiencies and the results from vertical
integration are encouraging in terms of
reduction in material costs. The growth in the
profits are after absorbing all plant operating
expenses (the revenues from these facilities are
expected subsequent to the approvals) for the
US/EU markets and an increased R&D expenditure.
The revenue expenditure for R&D stood at 814
lakhs in Q3 as compared to Rs.587 lakhs in Q2
and Rs.434 lakhs in Q1. The total R&D
expenditure in the nine months including both
revenue and capital expenditure stood at Rs.3243
lakhs. |
|
The Company has
received its first ‘Certificate of Suitability’
(COS) approval from European Directorate for
Quality Medicines (EDQM) for its product in the
therapeutic segment of Gastro-Enterology which
will enable the Company to enter into the
European Union (E.U) pharma market. |
|
The Company has
filed 5 DMFs and 2 ANDAs for the US markets.
Similarly the Company has filed 22 EDMFs/COS for
EU markets. |
|
China Operations:
Aurobindo Datong Bio Pharma has started
generating cash profits in the recent months. It
is expected to generate net profits in the
coming months. |
|
Product Mix:
The company’s efforts to enhance its business in
Non betalactams segments is progressing well.
Cephalosporins, SSPs and other products
constitute 38%, 32% and 30% of sales. |
|
Domestic branded formulation JV,
Citadel Aurobindo Biotech Ltd:
CABL operates in Indian market through four
divisions primarily focusing on a) CVS/CNS
segments b) Antivirals & immunology products c)
Pre and Post operative care at Surgeons d)
Physicians, Pediatricians and Gynecologists. The
CABL management has streamlined the operations
successfully and has recorded over Rs.75 crore
sales in the first nine months moving to the
target of reaching Rs.100 crore in the first
year of full operations. |
PRESS
ROOM 
